Compare YieldMax COIN Option Income Strategy ETF (CONY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax COIN Option Income Strategy ETF vs State Street SPDR S&P Biotech ETF — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $19.04 (market cap $370.88M), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 27.3× YieldMax COIN Option Income Strategy ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax COIN Option Income Strategy ETF for 41 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| CONY | XBI | |
|---|---|---|
Market Cap | $370.88M | $10.11B |
Volume | 595,904 | 12,903,266 |
Sector | Income / Options Overlay | Broad Market / Factor |
52-Week High | $76.50 | $169.55 |
52-Week Low | $17.73 | $104.99 |
Typical Hold Time | 41 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONY trades at $19.04, down 0.63% on the day, with a bearish technical signal from moving averages but bullish oscillators like RSI indicating potential oversold conditions. The ETF has experienced significant price erosion year-to-date, with a 51.3% decline noted in recent analysis, despite offering high distribution yields. Recent news highlights weekly dividend announcements and regulatory impacts on crypto-related stocks.
The outlook remains challenging due to structural NAV decay and full downside exposure to COIN. While the shift to a call spread strategy offers partial upside participation, the fund's high-risk profile and regulatory uncertainties present substantial headwinds for investors seeking stable returns.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
